During fetal prostate development, Sonic hedgehog (Shh) expression by the urogenital sinus epithelium activates Gli-1 expression in the adjacent mesenchyme and promotes outgrowth of the nascent ducts. Shh signaling is down-regulated at the conclusion of prostate ductal development. However, a survey of adult human prostate tissues reveals substantial levels of Shh signaling in normal, hyperplasic, and malignant prostate tissue. In cancer specimens, the Shh expression is localized to the tumor epithelium, whereas Gli-1 expression is localized to the tumor stroma. Tight correlation between the levels of Shh and Gli-1 expression suggests active signaling between the tissue layers. To determine whether Shh-Gli-1 
T HE PROSTATE GLAND is composed of a secretory epithelial parenchyma and a stroma consisting of smooth muscle cells and fibroblasts (1, 2) . The stromal cells elaborate components of the extracellular matrix and paracrine factors that regulate epithelial cell proliferation and differentiation (3) . The role of mesenchyme in directing growth and morphogenesis during embryonic prostate development is well established (4) . Similarly, a growing body of evidence indicates that the stroma may undergo phenotypic and/or genotypic changes that enhance prostate cancer growth (5, 6) . It has been shown, for example, that coinjection of prostate cancer-derived fibroblasts with tumorigenic epithelial cells into nude mice enhances tumor take and growth (7) (8) (9) (10) (11) (12) . Tumors may be able to recruit normal stromal cells to support tumor growth by inducing expression of a variety of angiogenic and growth factors in a paracrine fashion (reviewed in Ref. 13 ). The stromal reaction in cancer resembles the activity of stromal cells in wound healing and may create conditions that favor tumor progression (3) .
Hedgehog proteins in the prostate
Sonic hedgehog (Shh) is a secreted protein that acts as a potent inducer of morphogenesis and growth in diverse structures of the developing embryo (14 -19) . All known biological activity is associated with the N-terminal fragment of the protein (20, 21) . Shh exerts its effects by activating gene transcription in target cells expressing the hedgehog receptor Patched (Ptc-1) (22) . This interaction initiates a complex intracellular signal transduction cascade that activates the transcription factor Gli-1 (23) , one of three mammalian Gli genes related to the Drosophila segment polarity gene Cubitus interruptus (24) . Gli-1 activation results in increased expression of Gli-1 itself, Ptc-1, and target genes that regulate proliferation, differentiation, and extracellular matrix interactions (25) . Gli-2 encodes a transcriptional regulator that shares extensive homology with Gli-1 and may provide functional redundancy in the transcriptional response to Shh signaling. Gli-3 is believed to provide both positive and negative regulatory control over the expression of Shh target genes (reviewed in Ref. 26) .
Studies of prostate development suggest that Hedgehog signaling is critical for normal ductal morphogenesis (15, 27, 28) . Epithelial Shh expression is concentrated at sites of ductal bud formation and the tips of the growing ducts in which it activates Gli-1 and Gli2 expression in the adjacent mesenchyme. Negation of Shh signaling impairs the activation of Gli-1 and Gli-2 expression and inhibits ductal outgrowth (14 -15, 28) . Because this effect entails primarily an inhibition of epithelial cell proliferation, it suggested that epithelial Shh expression activates stromal-mediated paracrine signals that feed back and stimulate epithelial cell proliferation (15) .
LNCaP cells are human prostatic epithelial cells derived from a metastatic supraclavicular lymph node (29) . The LNCaP cell line forms xenograft tumors at high efficiency when coinjected with Matrigel into nude mice (30) . The xenograft tumors are composed of (human) LNCaP prostate cancer cells and host (mouse) derived stromal cells. We have taken advantage of this model to examine the influence of Shh signaling on prostate tumor growth. Our studies show that Shh expressed by LNCaP cells activates Gli-1 gene expression in host-derived stromal cells and that overexpression of Shh in the prostate cancer cells up-regulates stromal Gli-1 gene expression in vivo and accelerates xenograft prostate tumor growth. All of the evidence from these xenograft studies argues against autocrine signaling and suggests that Shh acts through the stroma to stimulate tumor cell proliferation.
Materials and Methods

Plasmids and cell lines
The human Shh overexpression vector, pIRES2-hShh-enhanced green fluorescent protein (EGFP), was made by cloning a 1.55-kb human Shh cDNA fragment (provided by Dr. Cliff Tabin, Harvard University, Boston, MA) into the EcoRI site of the cytomegalovirus promoter driven pIRES2-EGFP (Clontech, Palo Alto, CA). LNCaP cells (American Type Culture Collection, Manassas, Va) were transfected with pIRES2-hShh-EGFP or pIRES2-EGFP vector alone using Lipofectin (Life Technologies, Inc., Grand Island, NY) and subcloned by limiting dilution. One high Shh expressor clone [LNCaP
Shh(H)
] and one medium Shh expressor clone [LNCaP
Shh(M)
] were identified by green fluorescent protein (GFP) expression, and their Shh expression levels were confirmed by RT-PCR and Western blot.
LNCaP proliferation
Cells were plated at a density of 2 ϫ 10 4 cells/well in 24-well plates in complete media [RPMI 1640 containing 2 mm l-glutamine ϩ 1.5 g/liter sodium bicarbonate ϩ 4.5 g/liter glucose ϩ 10 mm HEPES ϩ 1 mm sodium pyruvate ϩ 10% fetal bovine serum (FBS)]. Cells were counted on a counter model ZF analyzer (Coulter, Fullerton, CA). Cell death, determined by Trypan blue exclusion, did not change under any of the treatment conditions. For cyclopamine experiments, subconfluent LNCaP and p2
PtcϪ/Ϫ (31) cells were incubated in medium containing 2% calf serum with or without 5 m cyclopamine (Toronto Research Chemicals, Ontario) for 7 d.
Xenograft model
All animal experiments were conducted in accord with institutional policies and Institutional Animal Care and Use Committee guidelines. LNCaP xenograft tumors were created by sc coinjection of LNCaP cells (1 ϫ 10 6 in 250 l PBS) with 250 l Matrigel into both flanks of adult male nude CD-1 mice (Charles River Laboratories, Wilmington. MA). Ten mice each were injected with each of the four cell lines. Tumors were measured weekly with a caliper and tumor volumes were calculated according to the formula (length ϫ width ϫ depth ϫ 0.5236) (32). The mice were followed up for 11 wk, although some cell lines experienced high mortality beginning at wk 9.
RT-PCR
Semiquantitative RT-PCR performed as previously described (16), using message for the ribosomal subunit protein, RPL-19, as an internal standard. Real-time quantitative RT-PCR was performed using TaqMan instrumentation (Applied Biosystems, Foster City, CA) and used genespecific primers and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as an internal standard. Total RNA isolated from cryopulverized tissue with Trizol (Gibco-BRL, Gaithersburg, MD) was subjected to reverse transcription using standard protocols. Species-specific primers for human Shh and mouse Gli genes and Ptc-1 were used to localize expression to the epithelial and stromal components of xenograft tumors. Primer sequences were as follows: Each PCR was run in duplicate and according to the manufacturer's recommendations and default settings.
Western blots
Lysates for Western blot analysis were prepared as previously described (33 
Histology and radioactive in situ hybridization
Tumor tissues were fixed in 4% paraformaldehyde overnight at 4 C, embedded in paraffin, sectioned at 5 m thickness, and stained with hematoxylin and eosin. In situ hybridizations were performed on paraformaldehyde-fixed, paraffin-embedded histological sections as described previously (34) . Mitotic indices were determined by scoring epithelial mitotic figures in 10 randomly selected high-power fields from representative sections of two xenograft tumors from each type. All counted mitotic figures were in tumor cells; no stromal mitotic figures were observed. 
Gli-luc assay
Human tissues
Pooled fetal prostate RNA from 20 -22 wk gestation and fetal brain RNA was obtained from Invitrogen (Carlsbad, CA). Adult human prostate tissues were obtained at Northwestern University from the following sources: 1) normal prostate tissues from organ donors at the time of organ harvest; 2) prostate cancer tissues from transurethral surgery in men with clinically advanced prostate cancer or by focal excision of tumor tissue from radical prostatectomy specimens; or 3) benign prostate hyperplasia (BPH) tissues from transurethral or simple prostatectomy. In each case, the diagnostic designation was histologically confirmed. Paired prostate cancer/ benign prostate tissue specimens were provided by the Tissue and Serum Repository (Kansas Cancer Institute, University of Kansas Medical Center, Kansas City, KS). After removal of the prostate from men undergoing radical prostatectomy for clinically localized prostate cancer, core biopsies were performed of presumed tumor and the equivalent site on the contralateral side of the specimen. Of the 20 specimens processed in this way, 11 pairs of tumor and benign tissue from the same patient were confirmed by histologic examination. Only these 11 sets were included in the final analysis. All procedures for tissue acquisition and analysis were approved by the institutional review boards of Northwestern University and Kansas University Medical Center.
Statistical analysis
Cell line growth culture. To assess growth of the four cell lines, a Gompertz growth model was fitted to each line. Day 0 cell counts were used as a baseline; counts for each line in subsequent days were expressed as percentages with respect to the d 0 average count. Natural (base e) logarithms of the percentages were obtained to make the variability across time and cell lines more homogeneous. A Gompertz model with line-specific asymptote and growth rate was estimated via Gauss-Newton optimization, as implemented in R v1.6.2 (36) . Model assumptions were assessed via residual plots, and, if warranted, parameter significance was tested via the approximate t test. Nonsignificant parameters were excluded and the model was refit.
Mouse tumor growth. Tumor size (cubic millimeters) was plotted against time for each mouse, with both sides combined. Mice that failed to reliably establish a tumor were not included in the analysis. Because straight lines provided a reasonably accurate summary representation of the growth patterns, least squares fits were obtained for each mouse by regressing tumor size at each time point and combining both sides. To assess differences in growth, the slopes of the regression lines were analyzed via a one-way nonparametric ANOVA (Kruskal Wallis) by ranking the slopes and performing an ANOVA on the ranks. All six pairwise comparisons between the cell least-squares mean rank were performed. Mitotic indices were compared by taking square roots of mitotic counts to stabilize the variance. Significant differences in the overall ANOVA (P ϭ 0.04) were further evaluated by split-plot models.
Human tissues. Gene expression analysis provided two sets of data. Data set 1 (DS1) consisted of 19 adult male prostate specimens: normal (n ϭ 7), prostate cancer (n ϭ 6), and BPH (n ϭ 6). Data set 2 (DS2) consisted of 11 paired tissues obtained at the University of Kansas Medical Center. Data from DS1 and DS2 were combined for statistical analysis: normal prostate (N, n ϭ 7), BPH (n ϭ 6), prostate cancer (PC, n ϭ 6), tumor (T, n ϭ 11), and benign (B, n ϭ 11). Differences in the mean gene expression among groups were tested with a one-way ANOVA (completely randomized design). The residuals were examined for evidence of violations in the assumptions. If needed, variance-stabilizing transformations were used. If the overall P value for the ANOVA was significant, pairwise contrasts were obtained for all possible group pairs. No adjustment was made for testing all contrasts. To assess whether Shh should be incorporated as a covariate, analysis of covariance (ANCOVA) was used for each of the three Gli genes. The model allowed for the possibility of differences in the intercept and the slope across groups. Model fit diagnostics were obtained via graphical assessment of the residuals. If warranted, transformations were used to ensure the model assumptions were not violated.
The plots and Gompertz fits were generated in R version 1.6.25.1 (36) . The ANOVA, ANCOVA, and Kruskal-Wallis analysis models were fit in SAS (release 6.12, SAS Institute, Cary, NC) (37).
Results
Expression of Shh and Gli in the adult human prostate
Shh is expressed in the human fetal prostate most abundantly between 11 and 16 wk of gestation, a period of ductal budding and intense ductal morphogenesis, and is markedly diminished by 34 wk of gestation (16) . An initial semiquantitative RT-PCR survey of Shh and Gli-1 expression in three normal adult prostate specimens (18, 30 , and 45 yr) and eight specimens of high grade (Gleason 8 -10) prostate carcinoma obtained by channel transurethral resection of the prostate, including two hormone-refractory tumors, revealed increased Shh and Gli-1 expression in the majority of the cancer tissues and an apparent correlation between the intensity of Shh and Gli-1 expression in the individual specimens (data not shown). These preliminary data encouraged us to more comprehensively characterize Shh and Gli gene expression in the human prostate. Two separate surveys were performed. The first compared Shh and Gli gene expression in seven normal prostate (N) specimens from organ donors 15-28 yr old, six BPH specimens obtained by TURP (n ϭ 4) or open prostatectomy (n ϭ 2), and six prostate cancer (PC) specimens obtained from glands removed by radical prostatectomy. The purpose of this survey design was to compare gene expression in normal prostate tissue from young adult men (N), in hyperplastic (benign) tissue from men without prostate cancer (BPH), and in specimens of human prostate cancer (PC). Expression of Shh, Gli-1, Gli-2, and Gli-3 was assayed by quantitative real-time RT-PCR and normalized to an internal expression standard of robust developmental Shh signaling activity, fetal brain RNA. This survey revealed that Shh expression is generally abundant in both benign (N and BPH) and cancer (PC) specimens (Fig. 1 ). Expression levels varied over a wide range. For statistical analysis of expression in the different groups, logarithmic and rank transformations were used to satisfy the assumptions of normality and homogeneous variance across groups. There was little difference between the two, so only the results for the logarithmically transformed (base e) expressions are shown (Fig.  1A) . ANOVA revealed no significant differences in levels of Shh expression (P ϭ 0.991) or Gli-1 expression (P ϭ 0.802) in the normal (N) and BPH specimens. Mean Shh and Gli-1 expression was nearly an order of magnitude higher in the cancer specimens (PC), compared with normal (N) and BPH, but given the wide variation in expression levels and the relatively small number of specimens examined, the differences were not statistically significant. For Gli-2 there were significant differences, with N different from both PC (P ϭ 0.0279) and BPH (P ϭ 0.0068).
The second survey was performed on a different group of patients with prostate cancer to determine whether there is relatively higher Shh expression in a focus of cancer, compared with the background expression in zone-homologous nonmalignant prostate tissue from the same gland. Paired specimens of tumor (T) and benign (B) tissue from 11 men undergoing radical prostatectomy were obtained by matching histologically confirmed tumor with histologically confirmed benign tissue obtained from the contralateral lobe. Statistical analysis revealed no significant differences in Shh or Gli gene expression between the cancer specimens and zone homologous tissues from the same group of patients (Fig. 1A , T vs. B; P ϭ 0.4645).
Active Shh signaling between epithelium and stroma
To determine whether the level of Shh and Gli-1 identified in the human prostate specimens is physiologically significant, we compared their expression to that seen in fetal brain where Shh signaling is known to play a critically important role in stimulating growth. Expression of Shh and Gli-1 in matched specimens from patients with prostate cancer (T and B) was typically the same order of magnitude as the fetal brain or greater (Fig. 2, A and B) . In situ hybridization localized Shh expression to the epithelium and Gli-1 expression to the periglandular stroma (Fig. 2, C and D) . The same pattern of localization was demonstrated in multiple specimens of prostate cancer and benign prostate tissue (data not shown). This distribution echoes the localization of the Shh and Gli-1 to the epithelium and mesenchyme in the developing prostate. Comparing the relative levels of Shh expression in Fig. 2A to Gli-1 expression in the corresponding specimens in Fig. 2B reveals an apparent correlation. ANCOVA (Fig. 1B) revealed a highly significant association between Shh and Gli-1 expression (P ϭ 0.0001) in normal, BPH, and prostate cancer tissue groups. This association is equivalent in all subgroups and suggests that epithelial Shh activity determines the stromal expression of Gli-1. The slopes do not differ across groups (P ϭ 0.3015), but the group-specific intercepts do differ (P ϭ 0.0357). Therefore, log (Gli-1) may be described by log (Shh) via a set of parallel straight lines with different intercepts for each group. ANCOVA revealed a similar correlation between Shh expression and expression of Gli-2 and Gli-3 (Fig. 1B) . Again, the slopes for the different groups are not significantly different for Gli-2 and Gli-3 (P ϭ 0.0853 and P ϭ 0.1260, respectively) but both log (Gli-2) and log (Gli-3) may be described by (Shh) as straight line predictor (P Ͻ 0.0002) with varying intercepts (P Ͻ 0.001).
LNCaP Shh expression drives stromal Gli-1 expression in xenograft tumors
LNCaP cells were stably transfected with a GFP expression vector containing the human Shh cDNA under the control of a cytomegalovirus promoter. (Fig. 3A) . However, Shh overexpression was not associated with activation of human Ptc-1, Gli-1, or Gli-2 in monolayer culture of LNCaP cells alone (Fig. 3, B-D) , arguing against autocrine signaling activity. The Shh-overexpressing and control cells exhibited identical morphology (not shown), and no significant differences in growth rate (P Ͼ 0.112) or maximal growth (P Ͼ 0.739) in culture (Fig. 3E ).
To exclude a contribution of ligand-independent (autocrine) activation of hedgehog signaling in the parental LNCaP, we used a chemical inhibitor of hedgehog signaling, cyclopamine, which interferes with activation of the postreceptor intracellular signal transduction mechanism (31). The LNCaP cell line exhibited no inhibition of LNCaP cell proliferation by 5 m cyclopamine, a concentration that significantly inhibits proliferation of PtcϪ/Ϫ cells (data not shown) (31) . When coinjected with Matrigel, LNCaP parent and Shhoverexpressing cell lines both form xenograft tumors consisting of nests of human prostate cancer cells and an intervening, well-vascularized fibroblastic stroma derived from the host mouse (30) . The tumors appeared indistinguishable (Fig. 4) , and review by a urologic pathologist identified no differences between xenografts made with the LNCaP parent cell line or cells overexpressing Shh. Human-and mousespecific primers were used to assay for Ptc-1, Gli-1, and Gli-2 expression to determine the target of Shh signaling. Xenograft tumors made with LNCaP parent and Shh-overexpressing cell lines show barely detectable human Ptc-1 expression and no human Gli-1 expression (not shown). In contrast, mouse Ptc-1 and Gli-1 were expressed in xenograft tumors made with the LNCaP parent cell line and demonstrated dramatically increased expression in xenograft tumors made with cells overexpressing Shh (Fig. 5, A-D) . These findings indicate that Shh secreted by LNCaP cells signals to mouse stromal cells present within the xenograft tumor and activates stromal cell Ptc-1 and Gli-1 expression in a paracrine loop. These findings were confirmed by radioactive in situ hybridization (Fig. 5, E-H) .
Shh overexpression accelerates tumor growth
Control cells and LNCaP cells overexpressing Shh formed tumors with equally high take rates (80 -100%) when coinjected with Matrigel. Neither demonstrated significant tumor formation even with prolonged (12 wk) follow-up when injected without Matrigel (data not shown). We therefore compared the growth rate of xenografts made by coinjection with Matrigel (Fig. 6) . Compared with both the parent cell line and GFP control, the medium and high Shh-overexpressing xenografts both exhibit significantly increased tumor growth rates. A slower rate of growth of the GFP control than the parent cell line is thought to reflect a nonspecific difference between the clonal GFP and parent cell lines. Additional experiments using nonclonal GFP and Shh overexpresser cell lines showed a comparable increase in tumor growth rate with Shh overexpression (our unpublished observations). Histologic examination of the tumors excluded an increase in stromal proliferation as an explanation of the increased tumor growth rate because both overexpresser and control xenografts are composed of an epithelium-rich tumor with a relatively small component of stromal tissue. Mitotic figures in the tumor stroma were scarce; in contrast, mitotic figures were very common in the tumor cell component of the xenograft (see Fig. 4 0.89, respectively; P ϭ 0.0016). These data support the observation that increased tumor growth results from an increase in tumor cell proliferation. The striking contrast between the similar growth rates of the Shh-overexpressing and control cells in culture and the marked differences in xenograft growth rates suggests that Shh overexpression stimulates tumor growth via a stromal mediated paracrine mechanism.
Discussion
Hedgehog signaling in normal and diseased prostate tissue
Epithelial-mesenchymal interactions driven by Hedgehog ligand are a central theme in the morphogenesis of several developing organs (38 -42). Inappropriate activation of the hedgehog signaling pathway has recently emerged as a key factor in oncogenesis and hyperproliferative disease, particularly in those organs in which Shh plays an important embryologic role (reviewed in Refs. 43, 44). Dahmane et al. (45) observed abundant Gli-1 expression in nine of 11 prostate cancer tissues examined and speculated that hedgehog signaling could play an important role in prostate cancer. This prompted us to more carefully examine hedgehog activity in benign and malignant adult prostate tissue. Our comparative analysis of prostate specimens from young adult men, men with BPH, and men with prostate cancer showed a trend toward higher Shh and Gli-1 expression in the cancer specimens, but this trend did not reach statistical significance. Even so, we found surprisingly high expression levels in these adult tissues: Shh and Gli-1 expression in most of the specimens exceeds the level of expression found in the fetal brain (see Fig. 4 ). This finding is in contrast to the mouse prostate in which expression in the adult is very low. The explanation may be that a wide range of histopathologic processes universally afflict the human prostate throughout the adult life span, including inflammation, hyperplasia, dysplasia atrophy, and proliferative atrophy as well as cancer. Indeed, we observed abundant Shh activity associated with foci of inflammation (our unpublished observations).
Comparison of Shh expression and Gli-1 expression in biopsies from contralateral lobes of the same gland showed a surprisingly strong correlation between expression in the tumor and benign tissue from the same patient (see Fig. 4 ). This was true despite wide variation in the levels of Shh and Gli-1 expression among individuals and suggests that the level of Shh signaling activity is a generalized characteristic of an individual's prostate. We observed a very tight correlation between Shh and Gli-1 expression in individual specimens of benign and malignant prostate tissue (see Figs. 1B and 4). Together with localization studies showing Shh and Gli-1 expression confined to the epithelium and stroma, respectively, this indicated that functional signaling by Shh from the benign epithelial and/or tumor cells drives Gli-1 expression in the prostatic stroma. Intriguingly, the strong correlation between Shh and Gli-1 in human specimens was clearly evident, even though the stromal/epithelial ratio varies significantly among specimens. This is best explained by restriction of Shh diffusion and localized signaling activity to the immediately adjacent stromal cells.
Hedgehog signaling in cancer
Ectopic activation of Sonic hedgehog signaling is a key event in the generation of sporadic (46, 47) and hereditary basal cell carcinoma (48, 49) as well as medulloblastoma (50, 51) . Mice heterozygous for Ptc-1 develop medulloblastomas (52) and, under some experimental conditions, skin lesions resembling basal cell carcinoma (53) . In these cancers, activation of the Hedgehog pathway is believed to induce proliferation in epithelial tumor cells via activation of cyclins and cyclin-dependent kinases (54) in an autocrine loop. Accordingly, Hedgehog antagonists are effective inhibitors of tumor growth in models of medulloblastoma (55) and basal cell carcinoma (35) . Recently ligand-dependent Hedgehog signaling has been described in a subset of human small-cell lung carcinomas and small-cell lung carcinoma cell lines tested (56) . Tumor growth is significantly inhibited by treatment with the natural Hedgehog antagonist cyclopamine in a xenograft model derived from one of these cell lines that is expressing Shh and Gli-1 concomitantly. Similar studies have shown Shh signaling promotes growth of pancreatic and upper gastrointestinal tumors (57, 58) . These studies show evidence of autocrine signaling but also noted activation of Shh target genes (Ptc) in the reactive stroma adjacent to the tumor.
As yet there is no evidence that oncogenic mutations of the Hedgehog pathway genes Ptc-1 or Smo exists in prostate cancer, and our localization studies did not show strong evidence for autocrine signaling in localized prostate cancer. Instead, our studies suggested that paracrine signaling from tumor cells to the adjacent stroma represents the major pathway of hedgehog target gene activation in prostate cancer. To examine the influence of such signaling on tumor growth, we Our survey of Hedgehog pathway genes in human prostate tissue reveals significant maintenance levels of Shh and Gli gene expression in the normal adult human prostate and comparably high levels of Hedgehog signaling in prostate cancer and benign prostatic hyperplasia. Given the lack of specificity of Shh expression for prostate cancer, how can it play an important role in cancer growth and progression? The answer may lie in the nature of the stromal response to that signal in prostate cancer. During prenatal mouse prostate development, Shh activates Gli gene expression in the adjacent mesenchyme, promotes epithelial proliferation and ductal growth (14, 15, 28, 29) . Later in prostate development, Shh appears to inhibit growth and induce differentiation of epithelial cells into postmitotic, terminally differentiated luminal cells (17) . The dichotomous actions of Shh at different stages of prostate development may be due to differing concentrations of active Shh peptide or coregulators such as activin A and TGF␤1 or a change in the state of stromal cell differentiation (17) .
Rowley and colleagues (59) have shown that prostate cancer-associated stromal cells are phenotypically different from the stromal cells of the normal prostate. Cancer-associated stromal cells exhibit a myofibroblast phenotype resembling the activated stromal cell associated with wound healing. Studies of tumor-associated stromal cells have shown enhanced capacity to promote tumor growth in vivo (reviewed in Refs. 60, 61) and demonstrated altered expression of genes such as matrix metalloproteinases and tissue inhibitors of metalloproteinases (3). More recently tumor-associated stromal cells and normal prostate stromal cells have been shown to exhibit different responses to paracrine stimulation with pigment epithelium-derived factor (62) (Kozlowski J., personal communication). The mechanism for stromal activation has not been defined and the mechanisms by which stromal cells influence tumor growth are also not well understood. However, the distinctive character of the stromal compartment associated with prostate cancer may set the stage for a categorically different response to Shh signaling. Whereas Shh signaling in the stromal context of the normal prostate may help regulate the balance between proliferation and terminal differentiation, a similar level of signaling in the context of a cancer-associated reactive stroma may induce paracrine signals that promote tumor cell proliferation. A better understanding of the stromal response to Shh signaling in normal and malignant prostate tissue will be critical to elucidating the mechanism by which Shh signaling promotes tumor growth.
